Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

203.05USD
23 Sep 2016
Change (% chg)

$-1.17 (-0.57%)
Prev Close
$204.22
Open
$202.78
Day's High
$204.30
Day's Low
$202.59
Volume
333,012
Avg. Vol
605,170
52-wk High
$231.32
52-wk Low
$147.73

Latest Key Developments (Source: Significant Developments)

Shire unit prices public offering of $12.1 bln senior notes
Tuesday, 20 Sep 2016 02:58am EDT 

Shire Plc :That its wholly owned subsidiary priced its inaugural public offering of $12.1 bln aggregate principal amount of senior notes.  Full Article

Shire priced its public offering of $12.1 bln aggregate principal amount of senior notes
Monday, 19 Sep 2016 08:13pm EDT 

Shire Plc: Shire prices public offering of senior notes . Priced its inaugural public offering of $12.1 billion aggregate principal amount of senior notes .Intends to use net proceeds to fully repay amounts outstanding under its January 2016 bridge facilities agreement.  Full Article

Shire priced its public offering of $12.1 bln aggregate principal amount of senior notes
Monday, 19 Sep 2016 07:20pm EDT 

Shire Plc: Shire prices public offering of senior notes . Priced its inaugural public offering of $12.1 billion aggregate principal amount of senior notes .Intends to use net proceeds to fully repay amounts outstanding under its January 2016 bridge facilities agreement.  Full Article

Shire District Court issues ruling in Hatch Waxman case regarding Shire's Lialda
Friday, 16 Sep 2016 04:49pm EDT 

Shire Plc : Court ruled that Cadilla Healthcare Ltd./Zydus Pharmaceuticals (USA) Inc.'s proposed generic version of Lialda does not infringe U.S. patent no. 6,773,720 ."believes that proposed Zydus product infringes '720 patent".  Full Article

Shire's Cuvitru gets FDA nod to treat primary immunodeficiency
Wednesday, 14 Sep 2016 07:00am EDT 

Shire Plc : Shire announces U.S. FDA approval of cuvitrutm [immune globulin subcutaneous (human), 20% solution] treatment for primary immunodeficiency .FDA granted approval for Cuvitru in adult and pediatric patients two years of age and older.  Full Article

Shire says prescription eye drop, xiidra 5% is now available in U.S.
Monday, 29 Aug 2016 10:47am EDT 

Shire Plc :Prescription eye drop, xiidra 5% is now available in the u.s..  Full Article

Shire launches Von Willebrand disease drug in the U.S
Tuesday, 9 Aug 2016 07:14am EDT 

Shire Plc :Announced U.S. launch of Vonvendi [von willebrand factor (recombinant)], only recombinant treatment for adults living with Von Willebrand Disease.  Full Article

Shire CEO says can 'hopefully do better' on Baxalta M&A target
Tuesday, 2 Aug 2016 07:00am EDT 

Shire Plc : Ceo says shire will not be engaged in larger scale m&a . Ceo says can 'hopefully do even better' than new $700 million cost savings target fin baxalta deal Further company coverage: [SHP.L] (Reporting By London Bureau) ((uk.online@reuters.com; +44 20 7542 7717;)).  Full Article

Shire announces FDA approval of Adynovate
Monday, 1 Aug 2016 07:00am EDT 

Shire Plc:Shire announces FDA approval of Adynovate with Baxject III reconstitution system.  Full Article

Shire recommends ADS holders reject TRC Capital's “mini-tender offer”
Friday, 29 Jul 2016 04:20pm EDT 

Shire PLC : Shire recommends ADS holders reject TRC Capital's “mini-tender offer” . Notified of unsolicited "mini-tender" offer made by TRC Capital to purchase up to 1 million ADS of Shire at price of $182.75/ads in cash . TRC Capital's offer is for approximately 0.33 percent of outstanding ordinary shares of shire ."Shire is not associated with TRC Capital, its mini-tender offer or mini-tender offer documentation".  Full Article

BRIEF-Shire unit prices public offering of $12.1 bln senior notes

* That its wholly owned subsidiary priced its inaugural public offering of $12.1 bln aggregate principal amount of senior notes Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)